N-Ethyl-L-histidine | 58813-25-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Ethyl-L-histidine
• 英文别名: (2S)-2-(ethylamino)-3-(1H-imidazol-5-yl)propanoic acid
• CAS: 58813-25-5
• 化学式: C₈H₁₃N₃O₂
• 分子量: 183.21
• InChiKey: GOJNPUFEMFOJBT-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  78
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Polyglutamic Acids Functionalised by Histidine Derivatives and Hydrophobic Groups and the Uses Thereof, in Particular for Therapeutic Purposes
  申请人：Soula Olivier

  公开号：US20100034886A1

  公开（公告）日：2010-02-11

  The invention relates to novel biodegradable materials based on modified polyamino acids and suitable, in particular, for vectoring active substance(s) (AS). Said invention also relates to novel pharmaceutical, cosmetic, dietary or plant protective compositions which are based on said polyamino acids. The aim of said invention is to provide a novel polymer raw material usable for vectoring the AS and capable to optimally meet all specification in this area: biocompatibility, biodegradability, ability to become easily associated with many active substances or to solubilise them and to release said active substances in vivo. The aim is attained to 30 carbon atoms. Said polyglutamates modified by histidine derivatives are soluble with pH lower than 5 and are easily and economically convertible into active substance vectorization particles which are able to form stable aqueous colloidal suspensions. On the contrary, said modified polyglutamates are insoluble in water with a physiological pH (7.4), and thereby have to be precipitated on an injection site in the case of a subcutaneous injection.

  该发明涉及基于改性聚氨基酸的新型可生物降解材料，特别适用于载荷活性物质（AS）。该发明还涉及基于这些聚氨基酸的新型药用、化妆品、膳食或植物保护组合物。 该发明的目的是提供一种新型聚合物原料，可用于载荷AS，并能够最佳地满足该领域的所有规范要求：生物相容性、生物降解性、能够轻松与许多活性物质结合或溶解它们，并在体内释放所述活性物质。该目的在30个碳原子处实现。 通过组氨酸衍生物改性的聚谷氨酸在pH低于5时可溶解，并且可以经济地转化为能够形成稳定水性胶体悬浮液的活性物质载体颗粒。相反，这些改性聚谷氨酸在生理pH值（7.4）下不溶于水，因此在皮下注射时必须在注射部位沉淀。
• Ligands of insulin degrading enzyme and their uses
  申请人：Université de Lille 2 Droit et Santé

  公开号：EP2371421A1

  公开（公告）日：2011-10-05

  The invention relates to ligands of insulin degrading enzyme and to their uses. The ligands of the invention are non peptidic and bind specifically to the exosite of insulin degrading enzyme. They are useful, in particular a use in the pharmaceutical field.

  该发明涉及胰岛素降解酶的配体及其用途。该发明的配体为非肽类，并特异性结合到胰岛素降解酶的外位点。它们在药物领域中特别有用。
• NOVEL HISTIDINE DERIVATIVES
  申请人：Nakazawa Yoshitaka

  公开号：US20100152459A1

  公开（公告）日：2010-06-17

  The present invention is to provide a novel compound which is useful as a pharmaceutical agent such as an analgesic. The present invention is to provide the novel histidine derivative having an excellent analgesic action and the like. The compound of the present invention has a very high intermigration into the blood upon oral administration and is very useful as a pharmaceutical agent, especially an analgesic for the treatment of acute or chronic pain diseases and of neuropathic pain diseases.

  本发明提供了一种新型化合物，可用作药物剂，如镇痛剂。本发明提供了具有出色镇痛作用的新型组氨酸衍生物等。本发明的化合物在口服后能够迅速进入血液循环，并且非常适用作为药物剂，特别是用于治疗急性或慢性疼痛疾病和神经病理性疼痛疾病的镇痛剂。
• Toxin-Like Polypeptides, Polynucleotides Encoding Same and Uses Thereof
  申请人：Linial Michal

  公开号：US20090305970A1

  公开（公告）日：2009-12-10

  An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide which comprises an amino acid sequence at least 90% identical to a sequence as set forth in SEQ ID NO: 1, wherein the polypeptide comprises an ion channel modulatory activity. Polypeptides and uses thereof are also disclosed.

  本文披露了一种孤立的多核苷酸，其包括一个核酸序列，编码一个多肽，其氨基酸序列至少与SEQ ID NO:1中所列序列相似度达到90％，其中该多肽具有离子通道调节活性。本文还披露了该多肽及其用途。
• Verfahren zur Herstellung von N-tau-substituierten Histidinderivaten, N-tau-substituierte Histidinderivate und ihre Verwendung
  申请人：DIAMALT AKTIENGESELLSCHAFT

  公开号：EP0129254A2

  公开（公告）日：1984-12-27

  Es wird ein Verfahren zur Herstellung von Nτ-substituierten Histidinderivaten der allgemeinen Formel beschrieben. Gemäß dem Verfahren wird ein Histidinderivat der allgemeinen Formel mit Phosgen umgesetzt, und das erhaltene Produkt wird dann alkyliert und anschließend mit Säure hydrolysiert. Es werden ebenfalls die bei dem Verfehren erhaltenen Produkte und ihre Verwendung beschrieben.

  通式为 Nτ 取代的组氨酸衍生物的制备方法 的工艺。根据该工艺，通式组氨酸衍生物 与光气反应，然后将得到的产物烷基化，随后用酸水解。 还描述了反应中得到的产物及其用途。